IMBiotechnologies Receives FDA Clearance to Market Occlusin ® 500 Biodegradable Microspheres in the U.S.

< p > OCL 500 is a microspherical agent in development for the treatment of highly vascularised tumours, including hepatocellular carcinoma (HCC; liver cancer), renal cell carcinoma (RCC; kidney cancer) and uterine fibroids. < /p > < p > 05/17/2010 < /p >
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news